
Drug maker Moderna's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook by $1 billion.
The company reported product sales of $3 to $3.1 billion in 2024 but lowered 2025's expected revenue range to $1.5 to $2.5 billion.